ReviewMolecular biology reports2026
Bacterial extracellular vesicles: emerging players in antimicrobial resistance and clinical translation.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) represents a critical and escalating global health challenge that extends beyond classical genetic mechanisms of resistance acquisition. Increasing evidence highlights extracellular vesicles (EVs) as key mediators of bacterial adaptation, intercellular communication, and resistance dissemination. Among these, bacterial extracellular vesicles (BEVs) play a central role by transporting diverse cargo, including antibiotic resistance genes, mobile genetic elements, antibiotic inactivating enzymes, and immunomodulatory factors. By facilitating horizontal gene transfer (HGT) and non-genetic resistance mechanisms such as antibiotic sequestration, extracellular neutralization, and biofilm reinforcement, BEVs contribute to the emergence and persistence of multidrug-resistant (MDR) infections. This review critically examines the biogenesis, cargo composition, and functional roles of BEVs in bacterial pathogenesis and AMR, while also discussing the complementary influence of host-derived EVs on infection dynamics and antimicrobial responses. We assess emerging evidence supporting EVs as non-invasive biomarkers for resistance surveillance and as adaptable platforms for vaccine development and targeted antimicrobial delivery. Finally, we highlight key unresolved challenges, including vesicle heterogeneity, limited understanding of cargo selection mechanisms, and the lack of standardized isolation and characterization protocols, which must be addressed to enable the clinical and translational integration of EV-based strategies in combating AMR.
Indexed as
Identifiers
42313295What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.